Astellas' $1.3B antibody strikes first in hot cancer field, extending survival in phase 3

Astellas Pharma’s $1.3 billion oncology bet has delivered a phase 3 win. The clinical trial linked the anti-CLDN18.2 antibody zolbetuximab to improved progression-free survival (PFS), moving Astellas a step closer to filing for approval.